Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Sep 17, 2026

Yarrow Bioscience, Inc. (YARW)

A forensic read on Yarrow Bioscience, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Grey Zone

Financial health

32.8

Distress distance

Watch

Earnings quality

Forensic signals

-1.2

P / E (ttm)

-95.4%

ROE

$286M

Market cap

13.8%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Yarrow Bioscience, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 32.8, placing it in the Grey zone. 3 forensic signals were flagged in its latest SEC filings, led by share count (stock split).

What the filings flag

n/m (stock split)

FY2022–FY2025

Share count (stock split). Diluted share count changed +1242% over the last 3 years to FY2025, but that includes a large one-time change around FY2023 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw +137.7%/yr figure isn't a real buyback/dilution read here.

405% of rev

FY2025

Stock-based comp load. Stock-based compensation ran 405% of revenue in FY2025 — about $0.05 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 5.9% a year, and the rate is falling. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.

$4M

FY2020–FY2020

Goodwill impairments. Took $4M of goodwill writedowns across 1 year (FY2020 ($4M)). Writedowns mean past acquisitions underperformed what was paid for them.

Key fundamentals

Latest Revenue$570,000.00

Revenue Growth YoY+13.8%

Revenue CAGR (3yr)+6.1%

Net Margin-4646.1%

Free Cash Flow-$33.1M

Return on Equity-95.4%

Debt / Equity0.00x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Yarrow Bioscience, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Sep 17, 2026. Forensic signals flag probability, not certainty.